Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GRCE is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
8 top institutions tracked
Sentiment: bullish
Last trade: buy 1 days ago
Red flags: 2
33 filers reported a long position in GRCE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Cerity Partners LLC | $1.9M | 849.1K | Unchanged |
| Eversept Partners, LP | $1.8M | 772.9K | +2.2% |
| BANK OF AMERICA CORP /DE/ | $1.1M | 494.7K | 0% |
| VANGUARD CAPITAL MANAGEMENT LLC | $934.6K | 411.7K | +2.5% |
| CITADEL ADVISORS LLC | $793.9K | 349.7K | +254.2% |
| Maven Securities LTD | $454K | 200K | New |
| Birchview Capital, LP | $272.4K | 120K | +140% |
| CANTOR FITZGERALD, L. P. | $227K | 100K | New |
| TWO SIGMA INVESTMENTS, LP | $219.9K | 96.9K | New |
| JANE STREET GROUP, LLC | $203K | 89.4K | -46.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.